A pivotal phase 3 clinical investigation, unveiled at the 2026 ATS International Conference, has presented compelling data for an investigational once-daily oral medication, identified as AD109, which has shown a remarkable reduction in breathing disruptions characteristic of obstructive sleep apnea (OSA). This innovative therapeutic agent is engineered to address the fundamental neuromuscular factors that precipitate airway collapse during nocturnal rest, offering a potentially transformative approach to managing this widespread sleep disorder. The findings from the SynAIRgy trial, meticulously detailed in the esteemed American Journal of Respiratory and Critical Care Medicine, underscore the drug’s capacity to substantially improve key indicators of OSA severity.
Participants who were administered AD109 exhibited a notable decrease in the frequency of apneic and hypopneic events, alongside improvements in nocturnal oxygen saturation levels. The study reported an average reduction of approximately 44% in the apnea-hypoxia index (AHI), a critical metric quantifying the number of breathing cessations or reductions per hour of sleep. In stark contrast, the placebo group experienced a mere 18% decrease in AHI, highlighting the distinct therapeutic effect of AD109. Beyond the primary endpoint, the drug also positively influenced other indices of sleep-related respiratory compromise, including the oxygen desaturation index and the overall burden of oxygen deficiency throughout the night.
A particularly encouraging outcome was the significant proportion of patients who experienced a clinical improvement substantial enough to reclassify them into a less severe OSA category, with over 40% achieving this milestone. Furthermore, a considerable 18% of the study cohort attained complete remission of their OSA, indicating a profound and potentially life-altering benefit. Dr. Patrick John Strollo, lead author of the study and a distinguished sleep medicine specialist at the University of Pittsburgh Medical Center, articulated the significance of these findings, stating that the results provide robust evidence that targeting the underlying neuromuscular dysfunction responsible for OSA can yield meaningful clinical improvements, aligning with a more sophisticated understanding of the disease’s biological underpinnings.
The development of AD109 emerges against a backdrop where continuous positive airway pressure (CPAP) therapy, while considered the current gold standard for OSA management, faces significant challenges in patient adherence and tolerability. Many individuals find CPAP devices cumbersome, intrusive, or otherwise difficult to sustain long-term, leading to a substantial unmet need for alternative treatment modalities. Dr. Strollo emphasized that AD109 could serve as a crucial alternative for those who are unable or unwilling to adhere to CPAP therapy, addressing a critical gap in the treatment landscape. He drew a parallel to other chronic conditions like cardiovascular disease, asthma, or type 2 diabetes, where the expectation is that the vast majority of diagnosed patients receive active treatment, a reality that has unfortunately not materialized for a significant portion of the OSA population. An oral medication designed to directly address the neuromuscular mechanisms driving airway collapse during sleep holds the promise of expanding the therapeutic armamentarium and offering effective options to a broader spectrum of patients who currently remain undertreated or entirely untreated.
AD109’s therapeutic mechanism is rooted in its unique formulation, which combines two distinct pharmacological agents: aroxybutynin and atomoxetine. This synergistic combination is designed to enhance the tone and function of the muscles in the upper airway, thereby reducing the propensity for the airway to narrow or completely collapse during the relaxed state of sleep. By bolstering the structural integrity of the pharyngeal muscles, the drug aims to maintain a patent airway throughout the sleep cycle, preventing the recurrent episodes of breathing cessation that define OSA.
The SynAIRgy trial, a meticulously designed six-month randomized controlled study, was conducted across 69 clinical sites in the United States and Canada, enrolling 646 adult participants diagnosed with mild to severe OSA. A key characteristic of the study population was that all participants had previously either declined CPAP therapy or had demonstrated an inability to tolerate it, making them ideal candidates to evaluate alternative treatments. The comprehensive data collected during the trial offers a robust assessment of AD109’s efficacy and safety profile in this specific patient demographic.
The observed benefits of AD109 were not confined to a particular subgroup of patients; rather, they were consistent across a diverse range of individuals, encompassing varying degrees of OSA severity and different anthropometric profiles. This broad applicability suggests that AD109 may have the potential to benefit a wide array of patients suffering from obstructive sleep apnea.
Regarding safety, AD109 demonstrated an acceptable profile, with reported side effects generally characterized as mild and consistent with the known properties of its constituent drugs. The most commonly reported adverse events included dry mouth, nausea, insomnia, and difficulties with urinary function. While these side effects were manageable for many, approximately 21% of patients discontinued the treatment due to their occurrence, a figure that will be crucial for assessing the drug’s real-world tolerability and informing clinical decision-making.
Further substantiating the clinical findings, a companion mechanistic review by the American Thoracic Society (ATS) is slated for publication in the American Journal of Respiratory Cell and Molecular Biology. Dr. Strollo highlighted the synergistic value of these peer-reviewed articles, explaining that their combined publication will provide a comprehensive and integrated perspective on OSA, linking late-stage clinical outcomes with the precise biological mechanisms targeted by AD109. This integrated approach is expected to bolster confidence in the therapeutic strategy and deepen the scientific community’s understanding of the disease.
The pharmaceutical company behind AD109, Apnimed, has taken significant steps toward bringing this novel therapy to patients, having submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The drug has already received Fast Track designation from the FDA, a testament to the recognized urgent need for effective and well-tolerated pharmacological interventions for OSA. Based on anticipated feedback from regulatory authorities, Apnimed projects a potential PDUFA target action date in the first quarter of 2027, contingent upon the FDA’s acceptance of the NDA for thorough review. This milestone represents a crucial step in potentially transforming the treatment landscape for millions affected by obstructive sleep apnea.
About the Author
